Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies

April 3rd 2018

Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Trastuzumab Regimen Extends PFS in Rare Endometrial Cancer

March 30th 2018

Adding trastuzumab to chemotherapy increased progression-free survival for patients with advanced HER2/neu-positive uterine serous carcinoma.

Dr. Santin on Rationale for Trastuzumab in Uterine Serous Carcinoma

March 30th 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the rationale for trastuzumab (Herceptin) in the treatment of patients with uterine serous carcinoma.

Dr. Slomovitz Discusses a Study of Everolimus/Letrozole or Hormonal Therapy in Endometrial Cancer

March 27th 2018

Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.

Protocol Effects Big Drop in Opioid Use After Gynecologic Surgery

March 25th 2018

Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.

Dr. Ledermann on the Treatment Landscape for Rare Gynecologic Cancers

March 23rd 2018

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the treatment landscape for patients with rare gynecologic cancers.

Dr. West on Pain Management for Endometrial Cancer

March 21st 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.

Klopp Comments on Optimizing Chemoradiation in Endometrial Cancer

March 20th 2018

Ann H. Klopp, MD, PhD, discusses optimizing the use of chemoradiation and the future of the treatment landscape in endometrial cancer.

Dr. Mutch on Frontline Treatment in Endometrial Cancer

March 16th 2018

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.

FDA Halts Combo Trial of Axalimogene Filolisbac Plus Durvalumab

March 14th 2018

The FDA has put a clinical hold on a phase I/II study of axalimogene filolisbac plus durvalumab (Imfinzi) for the treatment of patients with cervical cancer or head and neck cancer.

Dr. West on Relationship Between Diet and Endometrial Cancer

March 13th 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the relationship between diet and endometrial cancer.

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

March 13th 2018

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Dr. Klopp on the Future of Chemoradiation in Endometrial Cancer

March 9th 2018

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

Dr. Mutch on Biomarkers in Endometrial Cancer

February 27th 2018

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

Dr. Klopp Discusses Chemoradiation in Endometrial Cancer

February 26th 2018

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.

No OS Benefit With Chemoradiotherapy in High-Risk Endometrial Cancer

February 24th 2018

Adjuvant chemotherapy given during and after radiotherapy did not improve 5-year overall survival for patients with high-risk endometrial cancer in the phase III PORTEC-3 trial.

Dr. West on the Future of Treatment for Patients With Gynecologic Malignancies

February 23rd 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the future of treatment for patients with gynecologic malignancies.

Radiation Role Remains Uncertain in High-Risk Endometrial Cancer

February 20th 2018

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

Concomitant Chemoradiation Remains Standard in Locally Advanced Cervical Cancer

February 19th 2018

Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.

Dr. Arend on Novel Combination Strategies in Gynecologic Cancer

February 17th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.